Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, as over 60% of patients are diagnosed at a locally advanced stage with a high risk of recurrence. Although the landmark KEYNOTE-689 trial established neoadjuvant immune checkpoint inhibitor (ICI) therapy as a new standard of care, the pathological complete response (pCR) rate remains unsatisfactory at only 3.0%, highlighting an urgent need for optimized combination strategies. This prospective, single-arm, single-center clinical study aims to evaluate the safety, tolerability, and preliminary efficacy of a

Trial Details

NCT ID
NCT07572864
Phase
PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Engineered Mitochondrial Vaccine (IMP3-Mito)
  • Immune checkpoint inhibitor (ICI)
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Aged ≥ 18 years, both genders eligible.
  • Pathologically confirmed head and neck squamous cell carcinoma (HNSCC) meeting the following criteria:
  • Clinical stage II-IVB according to the AJCC 8th Edition (nasopharyngeal carcinoma is excluded);
  • Positive expression of IMP3 protein;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →